Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

920 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, Bannister D, Jovanovic J, Fleming R, D'Hooge F, Mao S, Marrero AM, Korade M 3rd, Strout P, Xu L, Chen C, Wetzel L, Breen S, van Vlerken-Ysla L, Jalla S, Rebelatto M, Zhong H, Hurt EM, Hinrichs MJ, Huang K, Howard PW, Tice DA, Hollingsworth RE, Herbst R, Kamal A. Harper J, et al. Among authors: herbst r. Mol Cancer Ther. 2017 Aug;16(8):1576-1587. doi: 10.1158/1535-7163.MCT-16-0825. Epub 2017 May 18. Mol Cancer Ther. 2017. PMID: 28522587
A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Xiao Z, Carrasco RA, Schifferli K, Kinneer K, Tammali R, Chen H, Rothstein R, Wetzel L, Yang C, Chowdhury P, Tsui P, Steiner P, Jallal B, Herbst R, Hollingsworth RE, Tice DA. Xiao Z, et al. Among authors: herbst r. Mol Cancer Ther. 2016 Apr;15(4):689-701. doi: 10.1158/1535-7163.MCT-15-0555. Epub 2016 Feb 15. Mol Cancer Ther. 2016. PMID: 26880266
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
Cho S, Zammarchi F, Williams DG, Havenith CEG, Monks NR, Tyrer P, D'Hooge F, Fleming R, Vashisht K, Dimasi N, Bertelli F, Corbett S, Adams L, Reinert HW, Dissanayake S, Britten CE, King W, Dacosta K, Tammali R, Schifferli K, Strout P, Korade M 3rd, Masson Hinrichs MJ, Chivers S, Corey E, Liu H, Kim S, Bander NH, Howard PW, Hartley JA, Coats S, Tice DA, Herbst R, van Berkel PH. Cho S, et al. Among authors: herbst r. Mol Cancer Ther. 2018 Oct;17(10):2176-2186. doi: 10.1158/1535-7163.MCT-17-0982. Epub 2018 Jul 31. Mol Cancer Ther. 2018. PMID: 30065100
SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
Kinneer K, Meekin J, Tiberghien AC, Tai YT, Phipps S, Kiefer CM, Rebelatto MC, Dimasi N, Moriarty A, Papadopoulos KP, Sridhar S, Gregson SJ, Wick MJ, Masterson L, Anderson KC, Herbst R, Howard PW, Tice DA. Kinneer K, et al. Among authors: herbst r. Clin Cancer Res. 2018 Dec 15;24(24):6570-6582. doi: 10.1158/1078-0432.CCR-18-1300. Epub 2018 Aug 21. Clin Cancer Res. 2018. PMID: 30131388
Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition.
Zhong H, Chen C, Tammali R, Breen S, Zhang J, Fazenbaker C, Kennedy M, Conway J, Higgs BW, Holoweckyj N, Raja R, Harper J, Pierce AJ, Herbst R, Tice DA. Zhong H, et al. Among authors: herbst r. Mol Cancer Ther. 2019 Jan;18(1):89-99. doi: 10.1158/1535-7163.MCT-18-0314. Epub 2018 Oct 23. Mol Cancer Ther. 2019. PMID: 30352801
Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR.
Mao S, Chaerkady R, Yu W, D'Angelo G, Garcia A, Chen H, Barrett AM, Phipps S, Fleming R, Hess S, Koopmann JO, Dimasi N, Wilson S, Pugh K, Cook K, Masterson LA, Gao C, Wu H, Herbst R, Howard PW, Tice DA, Cobbold M, Harper J. Mao S, et al. Among authors: herbst r. Mol Cancer Ther. 2021 Mar;20(3):541-552. doi: 10.1158/1535-7163.MCT-20-0351. Mol Cancer Ther. 2021. PMID: 33653945
Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer.
Bosco EE, Christie RJ, Carrasco R, Sabol D, Zha J, DaCosta K, Brown L, Kennedy M, Meekin J, Phipps S, Ayriss J, Du Q, Bezabeh B, Chowdhury P, Breen S, Chen C, Reed M, Hinrichs M, Zhong H, Xiao Z, Dixit R, Herbst R, Tice DA. Bosco EE, et al. Among authors: herbst r. Oncotarget. 2018 May 1;9(33):22960-22975. doi: 10.18632/oncotarget.25160. eCollection 2018 May 1. Oncotarget. 2018. PMID: 29796165 Free PMC article.
Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.
Kinneer K, Flynn M, Thomas SB, Meekin J, Varkey R, Xiao X, Zhong H, Breen S, Hynes PG, Fleming R, Bezabeh B, Chen CT, Wetzel L, Chen R, Dimasi N, Tai YT, Anderson KC, Herbst R, Howard PW, Hurt EM, Tice DA. Kinneer K, et al. Among authors: herbst r. Leukemia. 2019 Mar;33(3):766-771. doi: 10.1038/s41375-018-0278-7. Epub 2018 Oct 12. Leukemia. 2019. PMID: 30315237 No abstract available.
920 results